Dose Cancer Research Results
Dose, Dosage: Click to Expand ⟱
| Source: |
| Type: |
Drug dosage vs efficacy, and actual dosage number of research papers.
|
Lung, Lung Cancer: Click to Expand ⟱
Lung CSC (Cancer Stem Cells) markers (CD133, CD44, ALDHA1, Nanog and Oct4)
|
Scientific Papers found: Click to Expand⟱
| - |
vitro+vivo, |
Lung, |
A549 |
|
|
|
- |
vitro+vivo, |
Lung, |
PC9 |
|
|
|
Apoptosis↑, ROS↑, PDK1↓, NRF2↓, PDK1↓, Bcl-2↓, Casp9↑, Dose∅,
| - |
in-vitro, |
Lung, |
A549 |
|
|
|
- |
in-vitro, |
Melanoma, |
WM983B |
|
|
|
- |
in-vivo, |
NA, |
NA |
|
|
|
TumCG↓, eff↑, T-Cell↑, p‑IGF-1R↓, p‑Akt↓, PTEN↑, p‑eIF2α↑, OCR↓, ROS↓, ECAR∅, IL1↑, TNF-α↑, IL10↑, IGF-1R↓, eIF2α↑, PTEN↑, TCA↓, Glycolysis↓, selectivity↑, *toxicity∅, Dose∅,
| - |
in-vitro, |
Cerv, |
HeLa |
|
|
|
- |
in-vitro, |
Liver, |
HepG2 |
|
|
|
- |
in-vitro, |
BC, |
MCF-7 |
|
|
|
- |
in-vitro, |
Lung, |
A549 |
|
|
|
- |
in-vitro, |
Nor, |
HUVECs |
|
|
|
eff↑, Dose∅, *BioAv↑, selectivity↑, TumCP↓, Casp↑, PTEN↑, TSC1↑, mTOR⇅, Akt↓, PDK1↓, E6↓, E7↓, DNAdam↑, ROS↑, *BioAv↓, *BioEnh↑, *Half-Life∅,
| - |
in-vitro, |
Lung, |
A549 |
|
|
|
- |
in-vivo, |
Lung, |
NA |
|
|
|
AntiCan↑, Igs↓, lipid-P↓, ROS↑, Casp3↑, Casp9↑, ChemoSideEff↓, Dose∅,
| - |
in-vitro, |
Lung, |
A549 |
|
|
|
- |
in-vivo, |
Lung, |
NA |
|
|
|
- |
in-vitro, |
NA, |
BEAS-2B |
|
|
|
TumCG↓, CD31↑, P53↓, Dose∅, other↑, Apoptosis↑, Hif1a↑, selectivity↑,
| - |
in-vitro, |
Lung, |
Calu-6 |
|
|
|
- |
in-vitro, |
Lung, |
A549 |
|
|
|
TumCG↓, TumCCA↑, Dose∅, Bcl-2↓, cl‑PARP↑, MMP↓, Casp3↑, Casp8↑,
TumCG↓, Dose∅, DNAdam↑,
| - |
in-vitro, |
Lung, |
A549 |
|
|
|
- |
in-vitro, |
Lung, |
Calu-6 |
|
|
|
TumCD↑, MMP↓, ROS↑, GSH↓, Dose∅, eff↑,
Showing Research Papers: 1 to 8 of 8
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8
Pathway results for Effect on Cancer / Diseased Cells:
Redox & Oxidative Stress ⓘ
GSH↓, 1, lipid-P↓, 1, NRF2↓, 1, ROS↓, 1, ROS↑, 4,
Mitochondria & Bioenergetics ⓘ
MMP↓, 2, OCR↓, 1,
Core Metabolism/Glycolysis ⓘ
ECAR∅, 1, Glycolysis↓, 1, PDK1↓, 3, TCA↓, 1,
Cell Death ⓘ
Akt↓, 1, p‑Akt↓, 1, Apoptosis↑, 2, Bcl-2↓, 2, Casp↑, 1, Casp3↑, 2, Casp8↑, 1, Casp9↑, 2, TumCD↑, 1,
Transcription & Epigenetics ⓘ
other↑, 1,
Protein Folding & ER Stress ⓘ
eIF2α↑, 1, p‑eIF2α↑, 1,
DNA Damage & Repair ⓘ
DNAdam↑, 2, P53↓, 1, cl‑PARP↑, 1,
Cell Cycle & Senescence ⓘ
TumCCA↑, 1,
Proliferation, Differentiation & Cell State ⓘ
IGF-1R↓, 1, p‑IGF-1R↓, 1, mTOR⇅, 1, PTEN↑, 3, TumCG↓, 4,
Migration ⓘ
CD31↑, 1, TSC1↑, 1, TumCP↓, 1,
Angiogenesis & Vasculature ⓘ
Hif1a↑, 1,
Immune & Inflammatory Signaling ⓘ
Igs↓, 1, IL1↑, 1, IL10↑, 1, T-Cell↑, 1, TNF-α↑, 1,
Drug Metabolism & Resistance ⓘ
Dose∅, 8, eff↑, 3, selectivity↑, 3,
Clinical Biomarkers ⓘ
E6↓, 1, E7↓, 1,
Functional Outcomes ⓘ
AntiCan↑, 1, ChemoSideEff↓, 1,
Total Targets: 48
Pathway results for Effect on Normal Cells:
Drug Metabolism & Resistance ⓘ
BioAv↓, 1, BioAv↑, 1, BioEnh↑, 1, Half-Life∅, 1,
Functional Outcomes ⓘ
toxicity∅, 1,
Total Targets: 5
Scientific Paper Hit Count for: Dose, Dosage
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:15 Cells:% prod#:% Target#:1114 State#:% Dir#:6
wNotes=0 sortOrder:rid,rpid
Home Page